Blood Giant Grifols Acquires $1.9 Billion Stake in Shanghai RAAS
(Bloomberg) -- Grifols SA agreed to pay about $1.9 billion for a stake in Shanghai RAAS Blood Products Co., gaining a major foothold in China's booming blood-products market.
The Barcelona-based company will acquire a 26 percent stake in Shanghai RAAS in a noncash deal, making it the second-largest shareholder in the Chinese producer, Grifols said in a regulatory filing Thursday.
Demand is climbing in China for human serum albumin, a blood-plasma derivative used to treat liver diseases, with supplies limited by strict rules governing blood donation. As part of the deal, Grifols, the world's largest manufacturer of immunoglobulin, will provide technology and know-how to Shanghai RAAS, as well as engineering services in exchange for fees. The Chinese company will also become Grifols's exclusive distributor of plasma-derived products and transfusional diagnostic solutions in China.
In the transaction, Grifols will give Shanghai RAAS 45 percent of the economic rights and 40 percent of the voting rights of its U.S. subsidiary, called Grifols Diagnostic Solutions. The unit is valued at $4.3 billion, so the stake is worth about $1.9 billion.
As part of its push to both diversify away from the U.S. and grow in China, Grifols last year sealed a deal with Boya Bio-Pharmaceutical Group Co., known as Jiangxi Boya, to build and manage plasma collection centers.
Grifols's Australian rival CSL Ltd. paid $352 million in 2017 for a majority stake in Wuhan Zhongyuan Ruide Biological Products Co., which operates plasma collection centers. CSL acquired the rest of the company in June for a further $102 million.
To contact the reporter on this story: Rodrigo Orihuela in Madrid at rorihuela@bloomberg.net
To contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, John J. Edwards III, John Lauerman
©2019 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
